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1. Introduction
Alendronate, a bisphosphonate used to treat low bone density associated with osteoporosis,
has been shown to decrease fracture risk at both vertebral and non-vertebral sites. [1–3] It
achieves this risk reduction principally by increasing bone mineral density at the structural
level. Positive effects at the tissue level may also improve fracture risk early in treatment by
improving trabecular microarchitecture and reducing the number of trabecular stress risers
(unfilled resorption pits) at sites of remodeling. [4] Studies conducted in canine models have
shown, however, that one year of alendronate treatment is associated with decreased
toughness and increased microcrack density, though these two findings may be the result of
different mechanisms. [5] Furthermore, studies by Stepan et. al. found increased crack
density in osteoporotic women using alendronate compared to treatment-naïve osteoporotic
controls, whereas another study of osteoporotic women did not find significantly increased
microdamage frequency compared to cadaver controls. [6,7] A better understanding of the
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mechanistic basis of damage formation with alendronate treatment can provide new insight
into the underlying mechanisms of bone fragility.
Bone derives its ability to resist fracture by forming microdamage when subjected to
loading. Traditionally, microdamage in trabecular bone has been grouped into two different
morphological categories: linear microcracks and diffuse damage. Histologically, linear
microcracks are identified as individual, sharply defined cracks, while diffuse damage is an
of arrays of cracks. [8,9] It has been shown that different damage morphologies affect the
biomechanical properties of bone differently [10–12]. Diffuse damage formation plays a
significant role in prolonging the fatigue life of bone and resisting a catastrophic fracture.
[10,11] In contrast, linear microcracks can reduce bone strength and stiffness and are
traditionally associated with the terminal phase of fatigue fracture characterized by rapid
crack propagation and catastrophic failure. [10,11] Severe damage (defined by Moore and
Gibson as a primary crack with secondary cracks, or through-trabecular thickness cracks)
also occurs at a later stage in the fracture process [13,14] Although microdamage
accumulation has been documented with alendronate use, [6,7] its significance to bone
fragility is still unknown.
We have previously reported a specimen-specific finite element technique to assess
trabecular level stresses associated with microdamage initiation in bovine trabecular bone.
[15,16] With this technique, the relationship between local damage events and trabecular
stress magnitude can be directly assessed and associated with trabecular architectural
characteristics. The overall goal of the study was to investigate whether changes in bone
quality occurring after one year of alendronate treatment will result in an increased
propensity to form microdamage. The specific objectives were to (a) quantify the von Mises
stress state of trabeculae demonstrating different morphologies of damage and compare
between alendronate-treated and control groups, and (b) to determine if changes in
microarchitectural characteristics due to alendronate treatment are associated with damage
morphology.
2. Materials and Methods
2.1 Animals
Detailed methods regarding alendronate administration for this study have been previously
reported. [5] Briefly, one-year-old female beagle dogs were randomized into three groups
and treated with oral doses of saline (1.0 mL/kg/day) or alendronate (ALN, 0.2 mg/kg/day or
1.0 mg/kg/day) for one year. The ALN 0.2 and ALN 1.0 doses approximate the clinical
doses used for the treatment of postmenopausal osteoporosis and Paget’s disease,
respectively. The group treated with saline served as the control group. All procedures were
approved by the Indiana University School of Medicine Animal Care and Use Committee.
2.2 Sample Extraction
Twelve right distal femurs from beagle dogs (n=4 in each treatment group) were obtained
for analysis. One trabecular core from each specimen (diameter = 5 mm; length = 18 mm)
was extracted by coring through the condyle of the distal femur in the approximate principal
material direction using a trephine under constant irrigation with 0.9% physiological saline +
10 μmol/L protease inhibitor (E-64, Sigma Chemical) followed by sizing with a diamond
saw. The protease inhibitor (PI) was used throughout the experiment to minimize tissue
degradation. The specimens were wrapped in saline-soaked gauze and stored at −20°C until
testing.
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2.3 Microdamage labeling, Micro-CT imaging, and Mechanical Testing
Bone marrow was removed from trabecular cores using a water pik (WP-72W, WaterPik,
USA) to improve stain penetration, and one endcap was placed on the end of each sample.
Trabecular cores were stained for 8 hours in 0.02% Alizarin Complex One + 10 μmol/L PI
at 4°C then washed with distilled water for 1 hour to label pre-existing damage,
encompassing either in vivo damage or damage occurring from the core extraction. The ends
of the trabecular cores were glued into 5 mm deep stainless-steel endcaps to minimize end
artifact effects in the mechanical test. [17] Samples were imaged with micro-computed
tomography (μ-CT; μCT 40, Scanco Medical, Basserdorf, Switzerland) at a voxel resolution
of 20 μm prior to mechanical testing. Trabecular cores were then mechanically tested, in
which they were first preconditioned for 3 cycles to 0.1% strain then loaded in
displacement-controlled uniaxial compression (Mini Bionix 858, MTS Corp.) at a rate of
0.5% strain/second to the yield strain (determined to be 1.2% in preliminary testing) and
held for 3 hours. The apparent strain was calculated using a gauge length of the exposed
length of the bone measured with digital calipers plus half the length of each bone end
embedded in endcaps. [18] Throughout testing, bone cores were immersed in 0.9%
physiological saline + 10 μmol/L PI.
After testing, one endcap was removed with the diamond saw to improve stain penetration,
and cores were stained with 0.01% calcein to label test-induced microdamage for 8 hours at
4°C then washed with distilled water for 1 hour. [19,20] After staining, cores were fixed in
70% ethanol for 24 hours then dehydrated using a graded alcohol infiltration procedure.
Cores were embedded in methyl methacrylate in a prescribed orientation which allowed
visual registration with the 3D reconstructed μ-CT image, and 6 slides of thickness 150 μm
were obtained along the longitudinal axis with the diamond saw from each sample.
2.4 Microdamage Identification and Classification
Test-induced microdamage was identified based on the criteria that cracks are intermediate
in size (20 – 150 μm; larger than canaliculi but smaller than vascular channels), have sharp
borders, and a focus plane demonstrating depth of field. [5,6] Areas of diffuse staining with
no clearly defined cracks were not counted as microdamage. A classification system
published by Moore and Gibson was modified to group damage into three broad
morphological categories: severe, linear, and diffuse damage (Figure 1). [13] Severe damage
was classified as either microdamage consisting of one primary crack with minor secondary
cracks or cracks propagating through the thickness of the trabecula. Linear damage included
both single and parallel cracks, and diffuse damage consisted of cross-hatch damage that
was either equal in length and intensity (to distinguish it from severe damage) or damage
with a large area of distribution.
Damage was observed at 100× magnification using fluorescence microscopy and quantified
by an investigator blinded to the treatment group, then re-evaluated by a second investigator
also blinded to the treatment group. A 70% concordance rate in the number of damage
events identified between each investigatior was obtained, with the highest concordance rate
being in the severe group (88%), and the lowest concordance rate being in the linear damage
group (60%). Any differences in the count were reconciled between the two investigators, so
that the total damage count is confirmed by both investigators. An area of interest for
damage analysis was generated on each slide by excluding tissue less than 500 μm from
each sample edge. Damage incidents demonstrating three staining patterns were counted and
normalized by surface area (crack density, #/mm2). A damage incident is defined as a
discrete damage event, so that both linear and diffuse damage occurrences as classified by
Figure 1 would each count as one damage event. The three patterns of staining were 1) those
which fluoresced predominantly under red epifluorescence corresponding to the emission
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wavelength of alizarin, 2) those which fluoresced predominantly under green
epifluorescence corresponding to the emission wavelength of calcein, and 3) those which
fluoresced under both red and green epifluorescence equally in intensity and location.
2.5 Micro-CT Image Processing and Finite Element Analysis
3D micro-CT reconstructions of trabecular bone cores were thresholded to distinguish bone
from background, and automated distance transformation algorithms were used to compute
morphological parameters such as bone volume fraction, trabecular thickness and
connectivity, structural model index (SMI), and degree of anisotropy (DA). Mineralization
values were computed from attenuation values of grayscale μ-CT images based on
hydroxyapatite (HA) calibration standards.
Micro-CT images were used to create 3-D high-resolution finite element (FE) models for
estimating local stress distributions (FEA software, Scanco Medical, Basserdorf,
Switzerland). A homogeneous, linear elastic, isotropic model was used, and an initial tissue
modulus of 10 GPa and a Poisson ratio of 0.3 were assumed. Using Scanco software,
individual damaged and undamaged trabeculae identified first during histological
microdamage categorization were extracted from the 3-D reconstructed μ-CT image
manually (Table 1). By manually delineating trabeculae from the reconstructed μ-CT image
rather than the FEM estimation of stress distribution, the invetigators were not influenced by
the stress predictions when determining cutoff points. Values for von Mises stress along the
extracted trabeculae were obtained by averaging the values of all elements from the FEM
solution corresponding to the voxels of the extracted trabeculae (Figure 1). Stress results
were scaled to the back-calculated tissue modulus using a previously published procedure.
[21] Briefly, the apparent modulus obtained from mechanical testing within the elastic
region is compared to the predicted apparent modulus computed from finite element models
which used an initial estimate of the trabecular tissue modulus (10 GPa). The ratio of the
apparent modulus obtained from mechanical testing and predicted by finite element is
multiplied by the initial estimate of the tissue modulus to obtain the effective tissue modulus
based on mechanical testing results.
2.6 Statistics
All statistical tests were performed using MINITAB software (Minitab, Minitab Inc., USA).
Differences in global architectural parameters between the two treatment groups and the
control group were deduced using Kruskal-Wallis nonparametric tests. Differences in crack
density were determined with ANOVA analysis followed by Tukey pairwise comparisons.
p<0.05 was considered significant.
To determine differences in mechanical and architectural parameters of damaged and
undamaged trabeculae by treatment group and microdamage category, Friedman’s statistical
test was conducted for the treatment groups and the four damage categories. Kruskal-Wallis
nonparametric tests were used to determine differences between damage categories within
each treatment group, followed by post-hoc nonparametric pairwise comparisons. A
Bonferroni correction was used, as five measures (von Mises stress, mineralization,
trabecular thickness, SMI, and trabecular orientation) were made on each analyzed
trabeculae. This reduced the p value for a significant difference to p≤0.01. All data are
presented as mean ± standard error.
3. Results
Comparisons of alendronate’s effect on the global properties of trabecular bone are shown in
Table 2. Alendronate-treated trabecular bone exhibited trends towards increased bone
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volume fraction, mineralization, trabecular thickness, trabecular number, and connectivity
density, though none of these differences were significantly different than controls. There
were no significant differences between the apparent moduli obtained during mechanical
testing of alendronate samples compared to controls, nor were there differences in the back-
calculated tissue moduli of alendronate-treated samples compared to controls. No dose-
dependent differences in apparent properties were noted.
Figure 2 shows the crack density separated out as those cracks that were either alizarin or
calcein stained only, cracks exhibiting overlapping fluorescence, and total damage (all
cracks independent of color). There was a significantly higher density of calcein-labeled
cracks in the control group (0.74 ± 0.03 incidents/mm2) compared with the 0.2 mg/kg/day
treatment group (0.43 ± 0.07 incidents/mm2, p<0.05). Similarly, the crack density for cracks
which exhibited overlapping stains was increased in the control group (0.74 ± 0.03
incidents/mm2) compared with the 0.2 mg/kg/day treatment group (0.22 ± 0.05 incidents/
mm2). No significant differences in crack density were seen for alizarin-labeled cracks or in
total damage.
In order to determine the effects of alendronate treatment on tissue level biomechanical
properties, trabecular level von Mises stresses were compared to controls at microdamaged
sites. As shown in Figure 3, severely damaged trabeculae in the control group were under
the greatest von Mises stress, significantly greater than severely damaged trabeculae in both
of the alendronate treatment groups (p<0.001). A treatment effect was also discerned in the
linearly damaged group, where the von Mises stress state of the linearly damaged control
group was significantly greater than both alendronate treatment groups (p<0.01).
The stress state of trabeculae exhibiting different damage morphologies were also compared
within each treatment group. Severely damaged trabeculae in the control group were under
significantly greater stress than all other damage morphologies in the same group (p<0.01).
In both alendronate treatment groups, severely damage trabeculae were under greater stress
than linear and undamaged trabeculae in the same group (p<0.01). Finally, diffusely
damaged trabeculae in the ALN1.0 treatment group were under significantly greater stress
than linear and undamaged trabeculae in that group (p<0.01).
Alterations in local mineral density were analyzed by treatment group and damage
morphology. No differences due to dosage were observed, so the two treatment groups were
combined. Diffusely damaged trabeculae were significantly more mineralized in bone
treated with alendronate compared to controls (p<0.01). Similarly, undamaged trabeculae
were significantly more mineralized in treated compared with untreated controls (p<0.001).
Within the treated group, severely damaged trabeculae were less mineralized than
undamaged trabeculae (p<0.01, Figure 4a).
To determine whether trabecular architectural characteristics were associated with damage
morphology, trabecular thickness, structural model index, and trabecular alignment were
computed for each extracted trabecula undergoing stress analysis. No differences in any of
these architectural parameters were found between the two alendronate treatment doses;
thus, the data were pooled and compared to controls. Severely damaged trabeculae were
thinner than trabeculae sustaining other damage types in alendronate-treated samples
(p<0.01, Figure 4b); this was not true for the control group. Analysis of the SMI values for
damaged trabeculae revealed that severely damaged trabeculae subjected to alendronate
treatment were more rod-like than their diffusely damaged counterparts (p<0.01, Figure 4c).
Finally, the trabecular orientation, computed as the angle between the material axis and the
loading axis, was significantly more acute in severely damaged trabeculae compared to
undamaged trabeculae of the treated group (p<0.01). Severely, linearly, and diffusely
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damaged trabeculae were also more aligned with the loading axis compared with
undamaged trabeculae from the control group (p<0.01, Figure 4d).
4. Discussion
In this paper, a novel method of determining tissue-level mechanical and architectural
parameters associated with microdamage morphology was used to assess the effects of
alendronate on trabecular bone microstructure. Many studies have inferred that trabecular
von Mises stresses increase with damage severity, but this is the first study that quantifies
microstructural stresses by damage morphology. [13,22] This study concludes that
alendronate administration alters the tissue level biomechanical properties of trabecular
bone, resulting in a decreased von Mises stress necessary for initiation of severe and linear
microdamage.
Many previously published studies have utilized the fluorescent staining protocol developed
by O’Brien et al. to separate in vivo damage from test-induced damage. [20,23,24] In our
execution of this protocol, we were able to separate cracks formed in vivo from those
induced during uniaxial compression loading by examining their fluorescence under green
and red epifluorescence. Though total in vivo damage was not significantly greater in
alendronate treated bone, linear crack density was significantly increased in this population,
which is in agreement with previously published work. [5] However, it was difficult to
determine whether cracks which fluoresced under both red and green epifluorescence
equally are the product of crack propagation, double staining due to the sharing of calcium
binding sites between the two fluorophores, or filter interference. Due to these difficulties,
we chose to exclude cracks which exhibited this overlapping fluorescence from the stress
analysis due to the uncertainty of their origins.
Previous studies have correlated microdamage formation to trabecular shear stress,
suggesting that shear forces play a significant role in trabecular bone failure. [22,25,26] The
contribution of shear forces to failure can be evaluated with the von Mises stress parameter,
which is commonly used to predict yielding in complex loading conditions when the shear
stress reaches a critical value on the octahedral plane. Fyhrie et al demonstrated that von
Mises stress concentrations correlated with sites of cracking in mechanically tested and in
vivo damaged trabecular bone. [25] Our findings suggest that trabecular bone treated with
alendronate may be more susceptible to severe and linear microdamage formation because
of a decreased von Mises stress magnitude required to induce damage compared to controls.
Linear damage can reduce the biomechanical properties of bone and is traditionally
associated with the terminal phase of bone fracture characterized by rapid crack propagation
and catastrophic failure [10,11]; thus, alendronate administration may predispose trabecular
bone to the formation of more ominous microdamage patterns in the form of severe and
linear microdamage. [10,11,27] These observations may account for increased microcrack
density in trabecular bone treated with alendronate for one year as more damage would form
if the initiation threshold is lowered in this population. [5]
Alendronate treatment has been shown to increase the thickness and mineralization of
trabeculae, and this study corroborates that finding. [28] We found that thinner trabeculae
with decreased mineral density and rod-like morphology are more likely to sustain severe
damage in the treated samples compared to non-treated controls. The data suggest that the
vulnerability of trabeculae to damage based on thinness is relative to the average trabecular
thickness of the sample, for at the thickness of alendronate-treated severely damaged
trabeculae, untreated trabeculae at the same thickness were undamaged. There are two
possible mechanisms to explain this finding: either there is a decrease in bone quality factors
(tissue-matrix characteristics) in alendronate-treated trabeculae that promote damage
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formation, or architectural changes stemming from alendronate treatment that expose the
vulnerability of thinner trabeculae to damage. Since trabecular stresses in severely damaged
trabeculae were actually decreased compared to control samples, indicating that architectural
changes do not place greater stresses on thinner trabeculae, this suggests that some other
factor(s) related to bone quality facilitates severe damage formation in alendronate-treated
bone.
It is well documented that due to the suppression of bone remodeling, alendronate increases
tissue mineralization. [5,29] When mineralization density was compared based on trabecular
damage morphology, we found that mineralization was only increased in alendronate-treated
samples which were diffusely damaged or undamaged. Severely and linearly damaged
trabeculae in alendronate-treated samples were not differently mineralized compared to
control trabeculae with the same damage morphology. We have previously shown that
microdamage initiation occurs around areas of decreased mineralization, and speculate that
regions of low mineral/matrix ratio may result in greater local tissue compliance leading to
damage initiation. [30] This effect may be seen only at the 1 year stage of treatment as
matrix mineral will continue to age and stiffen as bone turnover declines.
Some aspects of the present study limit its broad applicability. This study was conducted in
bone from twelve animals, or four per treatment group. This limits the power of the study to
resolve stress differences due to treatment dose (1−β=0.49) or global architectural changes
like bone volume fraction with alendronate treatment (1−β=0.34). Our stress analysis was
conducted by analyzing almost 400 trabeculae, so we are more confident in the power of the
study to resolve differences in the stress state due to damage morphology (1−β approaches
1). Also, bone used for the microdamage analysis came from non-osteoporotic animals; thus,
it is difficult to apply conclusions to osteoporotic humans using bisphosphonate therapies.
However, our study focused on changes in intrinsic level properties of trabecular bone
elicited by alendronate use, and the bone physiology of humans and dogs is sufficiently
similar to allow such investigations. [31,32] Conclusions from this study are also limited by
the assumption of linearity, homogeneity, and isotropy at the microstructural level, which
somewhat limits the accuracy of the mechanical values obtained. However, Nagaraja et.al.
have shown that including inhomogeneous tissue moduli in finite element models offers
only a modest improvement in the correlations between microdamage initiation and local
stresses. Furthermore, strong correlations between stress magnitudes and damage severity
argue in favor of the finite element models’ accuracy in predicting tissue-level
biomechanical properties. [16] Additionally, the conservative nature of the statistical tests
used adds confidence to the conclusion that distinct differences in the state of stress of
trabeculae bearing different microdamage to patterns exist.
In conclusion, alendronate alters local mechanical and architectural properties of trabecular
bone which may increase its susceptibility to damage after just one year of treatment. This
study furthers our understanding of local tissue failure mechanisms, particularly in relation
to the factors influencing damage morphology formation. The clinical implications of these
findings are unclear, since increased risk of fracture with long-term alendronate use has not
been documented.
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Figure 1.
Microdamage description and classification, with FEA von Mises stress predictions. i.
Linear damage including a) single crack and b) parallel cracks, ii. Diffuse (crosshatch)
damage including c) equal crosshatching and d) large area distribution, iii. Severe damage
including e) one primary crack with minor secondary cracks and f) through-thickness cracks.
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Figure 2.
Total damage quantified based on fluorescence and plotted by treatment group. An increased
amount of damage occurred due to the mechanical test in the control group. The total
damage columns are created by totaling damage counted in the three previous columns for
each treatment group, and no significant differences were found. Bars represent significant
differences. p<0.05, mean ± SE. is plotted
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Figure 3.
Von Mises stress plotted by treatment group and damage morphology. The stress state of
trabeculae exhibiting severe and linear damage was decreased in both treatment groups
compared with controls. In the control group, severe damage was associated with the
greatest stress compared with all other damage groups. In both treatment groups, the stress
state of severely damaged trabeculae was significantly increased compared with linear and
undamaged trabeculae. Bars between damage morphologies within the same treatment group
indicate significant differences. p<0.01 indicates significance, mean + SE is plotted.
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Figure 4.
Trabecular mineralization and architectural characteristics plotted by treatment group and
damage morphology. There were no differences due to treatment dose, so the two samples
were combined. 4a. Trabecular mineralization is plotted with respect to damage morphology
and treatment; severely damaged trabeculae were less mineralized than undamaged
trabeculae in the treated group. 4b. Trabecular thickness is plotted with respect to treatment
and damage morphology; severely damaged trabeculae were significantly thinner than other
trabeculae in the treated group. 4c. Structural model index is plotted with respect to damage
morphology and treatment; severely damaged trabeculae are more rod-like than diffusely
damaged trabeculae. 4d. The angle between the principal material axis and the loading axis
is plotted; undamaged trabeculae were generally aligned perpendicular to the loading axis in
both treatment and control groups*indicates a significantly increased angle compared with
all other damage morphologies in the same group. Bars indicate significant differences
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between damage morphologies within the same group. p<0.01 indicates significance, mean
+ SE plotted
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Table 2
Apparent Properties of Alendronate-treated and Control Samples
0.2 mg/kg/day 1.0 mg/kg/day Control
Bone Volume Fraction (BV/TV) 0.20 ± 0.01 0.19 ± 0.007 0.13 ± 0.007
Mineralization (mg HA/ccm) 1040.3 ± 6.1 1040.3 ± 1.0 1011.9 ± 6.2
Trabecular Thickness (μm) 107.8 ± 5.4 106.7 ± 2.6 87.8 ± 2.3
Connectivity Density 24.5 ± 1.2 25.2 ± 1.2 18.7 ± 1.4
Structural Model Index (SMI) 1.12 ± 0.08 1.33 ± 0.04 1.43 ± 0.06
Degree of Anisotropy 1.43 ± 0.02 1.31 ± 0.02 1.41 ± 0.04
Trabecular Number 2.25 ± 0.04 2.21 ± 0.05 2.06 ± 0.05
Apparent Modulus (MPa) 872.7 ± 71.0 825.2 ± 57.6 600.0 ± 73.5
Tissue Modulus (GPa) 12.3 ± 1.9 13.1 ± 2.2 14.7 ± 1.1
No significant differences were noted.
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